HTDS - Hard to Treat Diseases (PINK)

[brushbuddy]

HGSI.bought into this compay and didnt to much for me.

[bdogsdad]

Sorry but I just don't know much about it. You might want to do some DD on HNAB, cheap right now with a lot of promise. Completed phase 2 with good results and a scheduled meeting with FDA regarding phase 3. Good Luck.

[shockdragon]

SHENZHEN, China, April 1 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS;
Welcome to HTDS Medical) announces that the company plans to proceed with a share buyback
program of its security.
As the company and its investors had been concerned with the company's share price being grossly
undervalued, the company sees this as a great opportunity to shore up the float with a
commencement of a share buyback program.
Neither the company nor its IR will comment on this topic further. The company will announce the
exact numbers as soon as this is beneficially advantageous to itself and its shareholders.
HTDS management is well positioned to complete this task with cash flows from the sale of some of
its disposed assets.
In other company news, the company has retained a California law firm to assist it in resolving
any issues with Pink Sheets regarding the "skull and bones" icon on HTDS security and the naked
short selling which effected the HTDS in the past, which now appear to be under check.
The company reminds its shareholders and followers to monitor PinkSheets.com Filing section and
also our IR company web site section "PRESS RELEASES AND FILINGS" TAB
http://www.minamargroup.net/ for non newsworthy corporate updates.
For any matters relating to retail investor queries or to send the company or its IR a message
please click on the "INVESTOR SUPPORT" TAB, or the direct link
The MinaMar Marketing Helpdesk.
Don't be a victim. Report a stock basher. The company is mindful that short sellers, the company
competitors and stock bashers stalk small cap Pink Sheets listed companies with hidden agendas.
Visit Exposing Stock Bashers and find out what criminal and civil actions the US
authorities are taking against web sites like investorshub.com and other posters, and the remedies
available to you as an individual investor.
Filings for this event are currently being reviewed and will be filed with Pink Sheets and Client
Support section in due course. To be included in company's email database for press releases,
industry updates, and non-weekly activity in the company that may or may not be news released,
please subscribe or opt in mailer at Mina Mar Group.
Safe Harbor Statement
Information in this filing may contain statements about future expectations, plans, prospects or
performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for
purposes of the safe harbor Provisions under the Private Securities Litigation Reform Act of 1995.
The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and
similar words and phrases are intended to identify such forward-looking statements. HTDS
Corporation cautions you that any forward-looking information provided by or on behalf of Hard to
Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this
filing constitutes or is intended as an offer to sell securities or investment advice of any kind.
Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such
forward-looking statements as a result of various important factors, some of which are beyond Hard
to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases,
Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s
management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the
sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise
additional capital to fund future operations, HTDS Corporation's ability to repay its existing
indebtedness, the uncertainties involved in estimating market opportunities and, in identifying
contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such
forward-looking statements are current only as of the date on which such statements were made.
Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any
forward-looking statement to reflect events or circumstances after the date on which any such
statement is made or to reflect the occurrence of unanticipated events.
CONTACT: For medical and scientific dialogue inquiry only, please contact
medicalinfo@htdsmedical.com; For any corporate matters, please contact
The MinaMar Marketing Helpdesk
SOURCE Hard to Treat Diseases
For medical and scientific dialogue inquiry only, please contact medicalinfo@htdsmedical.com; For
any corporate matters, please contact The MinaMar Marketing Helpdesk

© Thomson Reuters Limited. Click for restrictions.
Open in browser

[bdogsdad]

No one trusts what they say anymore.

[shockdragon]

BELGRADE, Serbia, April 6 /PRNewswire/ - Hard to Treat Diseases, Inc. (HTDS:PK), Welcome to HTDS Medical is pleased to announce that researchers from its Slavica BioChem (Homepage | Slavica Biochem) division have presented their results at the 8th World Congress on the Brain Injury, held in Washington, DC, March 10-14, 2010, under the auspices of The International Brain Injury Association (IBIA) internationalbrain.org. The Slavica team presented results which show the potential beneficial effects of hyperbaric oxygenation after traumatic brain injury. The IBIA World Congress is the largest gathering of international professionals working in the field of brain injury. Experts of different background took part in this Congress: scientists, physicians, psychologists and neuropsychologists, therapists, social workers, nurses and other professionals involved in the field of brain injury. The Organizers reported the 2010 meeting was the largest IBIA meeting ever organized, with more than 1000 participants and over 650 accepted abstracts.

Dr. Sanja Pekovic, Chief Project Scientist of HTDS, said: "This Congress was an excellent opportunity to get insight into the state-of-the-art research, covering all from the basic science to the clinical aspects of brain injury, as well as for establishing important contacts with international professionals involved in the brain injury research and the care of people with acquired brain injury. At the same time, we were able to present our results in a summary Poster format which was available for review by attendees. Hyperbaric oxygen (HBO) has been used as a primary or adjunctive therapy over the last 50 years with controversial results, both in experimental and clinical studies. However, mechanisms of HBO action have not been elucidated completely. Our results, obtained in the animal studies, shed more light to this which was very attractive for the numerous scientists and medical doctors. We had 3h long session with the attendees of our poster presentation in order to discuss all the questions on this topic.

Dr. Sanja Pekovic added: "The experiments were performed on rats, but we used the same type of hyperbaric chambers which are used for human subjects. These HBO treatments were conducted in collaboration with the medical doctors from the Hyperbaric Medical Center, School of Medicine, University of Belgrade, Serbia. Our previous experiments showed that repetitive HBO treatments significantly reduced neuronal loss and degeneration, suggesting that HBO was able to attenuate the effects of brain damage by reducing the progression of neuronal injury. These data encouraged us to continue our work. The most recent experiments (presented at the 8th World Congress on Brain Injury) revealed new beneficial effects of HBO treatment on glial scarring and inflammatory processes after traumatic brain injury".

In summary, Dr. Sanja Pekovic concluded: "Results presented here for the first time showed that HBO treatment reduces expression of the promoters of inflammatory responses. Additionally, our experiments point to HBO-induced suppression of astrogliosis and prevention of glial scarring after traumatic brain injury, and recommend HBO treatment as an attractive therapeutic tool for improving recovery from head injury."

In other company news, As the company does not subscribe to Pink Sheets filing service poster of the above release will be posted on the company web site Welcome to HTDS Medical shortly, and on the company' IR web site Mina Mar Group News and Filings Section www.minamargroup.net . Mr. Michael Arnkvarn CEO of Melem Secrets HTDS Skin Care Product Lines and Dr.Sanja Pekovic of Slavica Bio Chem have confirmed their attendance at the shareholders meeting on April 9 in Toronto Canada, where they will greet shareholders and present future vision for the company.

For any matters relating to retail investor queries or to send the company or its IR a message please click on the "INVESTOR SUPPORT" TAB, or the direct link The MinaMar Marketing Helpdesk.

Don't be a victim. Report a stock basher. The company is mindful that short sellers, the company competitors and stock bashers stalk small cap Pink Sheets listed companies with hidden agendas. Visit Exposing Stock Bashers and find out what criminal and civil actions the US authorities are taking against web sites like investorshub.com and other posters, and the remedies available to you as an individual investor.

Filings for this event are currently being reviewed and will be filed with Pink Sheets and Client Support section in due course. To be included in company's email database for press releases, industry updates, and non-weekly activity in the company that may or may not be news released, please subscribe or opt in mailer at Mina Mar Group.

Safe Harbor Statement

Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provisions under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

SOURCE Hard to Treat Diseases (HTDS)

Hard to Treat Diseases, Inc. (HTDS) Reports on Positive Influence of Hyperbaric Oxygenation on Recovery from Brain Trauma

[shockdragon]

Mina Mar Marketing Group (MMMG) Inc. (www.minamargroup.net), the peer of Mina Mar Group Inc. M&A Company (MinaMarGroup - International financial consulting firm and reverse merger transaction specialists.), announces that the company is expanding its marketing services to B2B and B2C vertical markets. This new division is in addition to its already existing investor awareness product lines. MMMG will offer a complete suite of marketing services for individual public or private business ventures.

Besides Investor Awareness, the company will now offer conventional marketing services such as B2C and B2B marketing to accommodate the broadest range of clients from all walks of life, whether they are public company clients of Mina Mar Group or private companies that need to raise product and or business awareness.

Over the years in the Investor Awareness marketing arena MMMG developed strong relationships across various market and platforms as well as a sizeable database of business contacts, investors (approximately 30,000) and shareholders (Approximately 600,000). MMMG plans to put this powerful database to a good use in its B2C and B2B marketing plans. The company has developed comprehensive marketing plans, marketing packages and custom made packages to meet financial and segmentation demands to suit all clients.

MMMG plans to assist several of its publicly listed companies in their marketing needs of product awareness. Recently MMMG conducted a beta launch of its services for Hard To Treat Diseases - Cosmetics Division which returned great results and began generating instant revenues and networking contacts for the client company. Similar marketing launches are planned for clients GOIG, SKGO, LDSR and RMDM for their product lines. A source close to the MMMG said "One of the biggest challenges facing our clients is the marketing costs. Many of our clients have great products with great profit margins built in, however the costs of getting their message out to the end user has always been for these companies a Ball and Chain Leg Shackle. Just as mina Mar Group pioneered the "Go Public Free" program we intend to offer to our clients a "Pay For Marketing With Your Profits" Program. Simply put, MMMG will do extensive marketing upfront for the client, free of initial charges or without any cash outlay by the client, and we will invoice and collect based on our performance based formula; with new and additional cash flows generated by MMMG marketing efforts.

To accommodate this expenditure both MMMG and MMG will be relocating to their newly acquired corporate headquarters in June 2010 at 5155 Spectrum way Building # 5 in Mississauga Ont.. The new headquarters of about 5,000 sq feet is being set up with a complete call centre features, arts department and advanced Internet marketing facilities.

About MMMG and MMG

Mina Mar Group focuses on the small-cap and micro-cap companies with revenues of less then 20 million dollars and/or assets of less then 3 million dollars. Mina Mar Group operates on both US and German exchanges, and serves their customers with complete Investor Relations (IR) services and Initial Public Offerings (IPO'S). The company recently opened an Australia office to service the Asutralia / New Zealand and the South Asian companies seeking to enter the German and USA public markets.

MMMG assists small issuers by tracking stock bashers, naked short sellers and reporting them to USA authorities or financing civil lawsuits. MMMG has already been awarded several judgments against stock char boards )for example investorshub.com) which offer stock bashers and short sellers a media to spew the dark propaganda against small companies with limited resources to defend themselves. MMMG cautions its readers against taking stock advice to "buy, sell or flip" from these chat boards as their authors may have a hidden agenda. It appears that the USA authorities are of the same opinion. Press Release: SEC Charges Eight Participants in Penny Stock Manipulation Ring; 2009-117; May 21, 2009 please Visit Exposing Stock Bashers to learn more.

The 2nd annual shareholder conference will be held April 9 2010 in Toronto. MMMG invites all followers of client issuers and MMMG to attend at the Marriott Hotel; Toronto Airport.

To receive future updates via email, including quarterly **********s and company updates that may not be newsworthy, however important to the reader and followers of the company, please sign up today free at Mina Mar Group

To find out more about MMMG and MMG visit www.minamargroup.net and MinaMarGroup - International financial consulting firm and reverse merger transaction specialists.

Disclosure

The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. MMG encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and MMG makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. MMG and its affiliates are not registered investment advisors or broker-dealers. MMG has been advised that the investments in companies profiled are considered to be high risk and use of the information provided is at the investor's sole risk. MMG also advises that the purchase of such high risk securities may result in the loss of some or all of the investment. Investors should not rely solely on the information presented. Rather, investors should use the information provided by the profiled companies as a starting point for doing additional independent research on the profiled companies in order to allow the investor to form his or her own opinion regarding investing in the profiled companies. Factual statements made by the profiled companies are made as of the date stated and are subject to change without notice. Investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. MMG makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through MMG. MMG owners may or may not hold positions in the companies that are profiled. The information contained herein contains forward-looking information within the meaning of Section 27A of the Securities Act of 1993 and Section 21E of the Securities Exchange Act of 1934 including statements regarding expected continual growth of the company and the value of its securities. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 it is hereby noted that statements contained herein that look forward in time which include everything other than historical information, involve risk and uncertainties that may affect the company's actual results of operation. Factors that could cause actual results to differ include the size and growth of the market for the company's products, the company's ability to fund its capital requirements in the near term and in the long term, pricing pressures, unforeseen and/or unexpected circumstances in happenings, pricing pressures, etc. Investing in securities is speculative and carries risk. Past performance does not guarantee future results.

PR-USA.net - Mina Mar Marketing Group Broadens Its Marketing Appeal

[shockdragon]

OTTAWA, April 8 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS; Welcome to HTDS Medical) Collagenna Skin Care Products will be officially presented to the Swiss Pharmaceutical and Health Care Sector at the upcoming Health Pharma Bern Expo April 10/11, 2010. Health and Pharma: Home

Collagenna Skin Care Products' exclusive distributor Alphaderm Body and Wellness, ALPHADERM GMBH — Body & Wellness will be exhibiting at the show. Collagenna's Products will be front and center. As well, Alphaderm's CEO, Irene Grimm has been added to the list of speakers. She will present several public presentations to the audience attending the exposition. The Collagenna Skin Care line to the participants will be showcased. Products will be available for purchase in the Alphaderm/Collagenna booth.

Michael Arnkvarn, CEO of Collagenna Skin Care Products stated, "We are very excited about the feedback that we have been receiving from the Swiss market. The products are giving the expected results and Alphaderm is ordering on a regular basis. In fact, they have hired an experienced skin representative who will be dedicated to the promotion of the Collagenna Skin Care line. This exposition will allow us to maintain the momentum that the initial sales efforts have created. Alphaderm's main market is with hotels, spas and skin care clinics but we both agree that we would entertain some distribution via retail outlets such as pharmacies and this will be an excellent opportunity to test the waters."

In other news Michael Arnkvarn, CEO of Collagenna Skin Care Products invites all shareholders and followers of HTDS to attend the company shareholder Expo in Toronto April 9th at the Marriott Airport hotel. Shortly the company will be making an update on its recently announced share buyback program and the progress made to date.

The company reminds our shareholders and followers that the company does not subscribe to the PinkSheets.Com Filing Service. Its IR company web site section "NEWS and FILING" TAB www.minamargroup.net should be reviewed by its followers for further updates on this and other business matters. Non-newsworthy events are not press released however posted on this separate support sites to keep our followers advised of day-to-day events, and the company corporate web site. For any matters relating to retail investor queries or to send us the company directly a message please click on the "INVESTOR SUPPORT" TAB or this direct link The MinaMar Marketing Helpdesk.

To be included in company's email database for press releases, industry updates, and non-weekly activity at the company that may or may not be news released, please subscribe or opt in mailer at Mina Mar Group.

[shockdragon]

April 13, 2010 1:28 PM EDT

SHENZHEN, China, April 13 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS; Welcome to HTDS Medical) announces that the company management is proceeding with the company Share Buyback Program as per the news of April 1 2010 in an effort to raise the value of the company security.

HTDS management plans to continue with the Program, using financing from sales of some of the company disposable assets. HTDS management is of opinion that this financing should be sufficient to raise the price of the security to true worth of HTDS and satisfy all shareholders and investors.

HTDS' management will advise the public on all new developments regarding the share reduction program and all other news related to the HTDS security.

HTDS CEO Terry Yuan said "It is my understanding that the HTDS team of Slavica Bio Chem and Collagena Skin Care did a wonderful job at the Business Expo and Shareholders Conference. Unfortunately, I was unable to attend to meet and greet many HTDS shareholders that came by the HTDS booth. A soon to be contract announcement will explain why I needed to focus all my attention on bringing that contract to a fruition. It is my understanding that a group from USA will be visiting Slavica Bio Chem in Serbia for discussions and cooperation's on some of the projects that division is working on at the end of April. The USA group is showing particular interest in the Slavica rejuvenated medical project (see Filing Nov 24) http://www.otcmarkets.com/otciq/ajax...d.pdf?id=26604 and other medical work the team is engaged in. HTDS will report back shortly after the conclusion of the USA group due diligence is completed, and we as a company will report back to our followers the significant and positive outcome this will have on the entire HTDS organization."

The company reminds its shareholders and followers to monitor our IR company web site section "PRESS RELEASES AND FILINGS" TAB http://www.minamargroup.net/ for non newsworthy corporate updates.

For any matters relating to retail investor queries or to send the company or its IR a message please click on the "INVESTOR SUPPORT" TAB, or the direct link The MinaMar Marketing Helpdesk.

Don't be a victim. Report a stock basher. The company is mindful that short sellers, the company competitors and stock bashers stalk small cap Pink Sheets listed companies with hidden agendas. Visit Exposing Stock Bashers and find out what criminal and civil actions the US authorities are taking against web sites like investorshub.com and other posters, and the remedies available to you as an individual investor.

Filings for this event are currently being reviewed and will be filed with Pink Sheets and Client Support section in due course. To be included in company's email database for press releases, industry updates, and non-weekly activity in the company that may or may not be news released, please subscribe or opt in mailer at MinaMarGroup - International financial consulting firm and reverse merger transaction specialists..

Safe Harbor Statement

Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provisions under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

CONTACT: For medical and scientific dialogue inquiry only, please contact medicalinfo@htdsmedical.com; For any corporate matters, please contact The MinaMar Marketing Helpdesk

SOURCE Hard to Treat Diseases


StreetInsider.com - Hard to Treat Diseases (HTDS) Share Reduction Program Target 500 Million Shares

[shockdragon]

Hard to Treat Diseases to Proceed with Share Buyback Program in Effort to Raise Shareholder Value

New York, New York 4/15/2010 05:30 PM GMT (TransWorldNews)



Hard to Treat Diseases (Pink Sheets: HTDS) will proceed with the Share Buyback Program following the news on April 1, 2010 in an effort to raise the value of the company’s shares.



Xplosive Stocks, an online financial publication, provides investors timely stock market information.

Sign Up Today for our Free Stock **********



HTDS management plans to continue with the program, using financing from sales of some of their disposable assets. HTDS management is under the opinion that this financing should be enough to raise the price of the security to the true value of HTDS.



HTDS is a holdco of a China based Shenzhen Mellow Hope Pharm Industrial Co., Ltd. Mellow Hope is the biggest exporter of Biological Vaccines in China. Based on the cooperation with Institutes of Medical Biology and Pharmaceutical manufacturers, Mellow Hope provides a wide range of vaccines with high quality, safety and efficacy.



Sign up for the free Xplosive Stocks **********. Investors interested in receiving small cap stock alerts through the penny stock ********** published by Xplosive Stocks can sign up for free by visiting our website.



About Us



Xplosive Stock is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We focus on Xplosive Stocks and track small cap companies that are on the brink of a financial breakout. To feature a company on our website please contact us at the email listed below.



Please click here to read the full disclaimer.

Hard to Treat Diseases to Proceed with Share Buyback Program

[shockdragon]

Hard to Treat Diseases (HTDS) Collagenna Skin Care Products Reaches Distribution Agreement for Western Canada and Arizona



OTTAWA, April 20 - Hard to Treat Diseases (HTDS; Welcome to HTDS Medical) Collagenna Skin care Products has entered into an exclusive distribution agreement with the Beauty Products Distributor Just Nailz of Calgary, Alberta. www.justnailz.com

Just Nailz & Beauty Supplies is a professional beauty wholesaler and training centre, specializing in esthetics and UV gel nails. Its "professional" beauty products are sold to salons and beauty schools throughout the province of Alberta and will soon be opening up a distribution business for the market of Arizona.

Deborah Jacklin, founder and CEO of Just Nailz quoted "We heard about the Collagenna Skin Care Line and were intrigued by its natural, premium ingredients. Today's beauty industry is demanding premium natural skin care products with effective and active ingredients, targeting lines and wrinkles. Collagenna fits this criteria perfectly. Many of our salon customers are telling us how excited they are that we are bringing on a premium, natural skin care line that can be used by the professional esthetician, but also retailed to the end retail customer. Through our own personal testing of the line, we found it exceeded our expectations. I know our customers are going to be extremely pleased with the performance. It seems our enthusiasm has spread, and we now have a waiting list of salons wanting to get started with this line when it arrives to our showroom this week."

The company reminds our shareholders and followers that the company does not subscribe to the PinkSheets.Com Filing Service. Its IR company web site section "CLIENT SUPPORT" TAB www.minamargroup.net or this direct link Mina Mar Marketing Group - Kayako SupportSuite Help Desk Software should be reviewed by its followers for further updates on this and other business matters. Non-newsworthy events are not press released however posted on this separate support sites to keep our followers advised of day-to-day events, and the company corporate web site. For any matters relating to retail investor queries or to send us the company directly a message please click on the "INVESTOR SUPPORT" TAB or this direct link The MinaMar Marketing Helpdesk.

To be included in company's email database for press releases, industry updates, and non-weekly activity at the company that may or may not be news released, please subscribe or opt in mailer at MinaMarGroup - International financial consulting firm and reverse merger transaction specialists..

Safe Harbor Statement

Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

CONTACT: For medical and scientific dialogue inquiry only, please contact medicalinfo@htdsmedical.com; For any corporate matters, please contact The MinaMar Marketing Helpdesk

SOURCE Hard to Treat Diseases

Hard to Treat Diseases (HTDS) Collagenna Skin Care Products Reaches Distribution Agreement for Western Canada and Arizona | Earth Times News